Trials / Completed
CompletedNCT06647628
A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005)
A Randomized, Double Blind Clinical Trial to Assess Safety, Tolerability and Pharmacokinetics of MK-1708 in Healthy Elderly Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 65 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to learn about the safety of MK-1708, and how well elderly people tolerate it. The study will also measure what happens to MK-1708 in a healthy elderly person's body over time (pharmacokinetic or PK study). Researchers will learn if at least 1 dose level of MK-1708 will be safe, well-tolerated, and will be above a certain level in people's blood after 24 hours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-1708 | MK-1708 oral suspension |
| DRUG | Placebo | Placebo oral suspension |
Timeline
- Start date
- 2024-11-04
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
- First posted
- 2024-10-18
- Last updated
- 2025-05-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06647628. Inclusion in this directory is not an endorsement.